In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merck buys Insmed's follow-on biologics assets for $130mm

Executive Summary

Protein manufacturer Insmed is selling its follow-on biologics assets to Merck & Co. for gross proceeds of about $130mm (net $123mm after taxes and costs).
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Full Acquisition
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register